Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro
暂无分享,去创建一个
Tetsuro Baba | K. Sugio | K. Yasumoto | T. Baba | M. Takenoyama | Takeshi Hanagiri | Yoshiki Shigematsu | Makiko Mizukami | Yoshinobu Ichiki | Mitsuhiro Takenoyama | Kosei Yasumoto | Y. Ichiki | Takashi Fukuyama | Sousuke Yamada | Yoshika Nagata | Masakazu Sugaya | Kenji Sugio | Takashi Fukuyama | T. Hanagiri | Y. Shigematsu | Y. Nagata | M. Sugaya | M. Mizukami | S. Yamada | Makiko Mizukami
[1] A. Levinson,et al. Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1 , 1990, The Journal of experimental medicine.
[2] R. Whyte,et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma , 1994, The Journal of experimental medicine.
[3] J. Siegfried,et al. Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. , 1988, Cancer research.
[4] F. Thunnissen,et al. Histological typing of lung and pleural tumours: third edition , 2001, Journal of clinical pathology.
[5] C. J. Burger,et al. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. , 1994, Journal of immunology.
[6] Margarita Martinez-Moczygemba,et al. Biology of common β receptor–signaling cytokines: IL-3, IL-5, and GM-CSF , 2003 .
[7] M. Nakajima,et al. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Keller,et al. Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.
[9] W. Lindenmaier,et al. Provision of 4-1BB Ligand Enhances Effector and Memory CTL Responses Generated by Immunization with Dendritic Cells Expressing a Human Tumor-Associated Antigen1 , 2003, The Journal of Immunology.
[10] K. Sugio,et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. , 2002, Chest.
[11] D. Metcalf. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. , 1986, Blood.
[12] M. Awwad,et al. The immune response to tumors. , 1989, Transplantation proceedings.
[13] R. J. Hocking,et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.
[14] H. Broxmeyer,et al. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. , 2005, Blood.
[15] M. Martinez-Moczygemba,et al. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. , 2003, The Journal of allergy and clinical immunology.
[16] K. Yasumoto,et al. Successful Induction of Tumor‐specific Cytotoxic T Lymphocytes from Patients with Non‐small Cell Lung Cancer Using CD80‐transfected Autologous Tumor Cells , 2001, Japanese journal of cancer research : Gann.
[17] R. Prehn. Tumor immunogenicity: how far can it be pushed? , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Burdick,et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.
[19] N. Cascinelli,et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.
[20] P. Kondaiah,et al. Autocrine induction of tumor protease production and invasion by a metallothionein‐regulated TGF‐beta 1 (Ser223, 225). , 1992, The EMBO journal.
[21] H. Broxmeyer,et al. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. , 2002, Blood.
[22] A. Galloway,et al. VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis , 2006, Proceedings of the National Academy of Sciences.
[23] C. Angeletti,et al. Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL -2-mediated neovascularization , 2000, British Journal of Cancer.
[24] R. Kerbel,et al. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[25] Anita B. Roberts,et al. REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .
[26] Y. Gong,et al. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. , 2001, Journal of immunology.
[27] Y. Gong,et al. Tumor-Derived TGF-β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine1 , 2003, The Journal of Immunology.
[28] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[29] J. Mitchell,et al. Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. , 2002, Cytokine.
[30] M. Sporn,et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[31] G. Trinchieri,et al. Regulation of NK cell functions by TGF-beta 1. , 1995, Journal of immunology.
[32] H. Taguchi,et al. Effect of serum deprivation on constitutive production of granulocyte‐colony stimulating factor and granulocyte macrophage‐colony stimulating factor in lung cancer cells , 2004, International journal of cancer.
[33] A. Roberts,et al. Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.
[34] T. Tsushima,et al. Transforming growth factor‐β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma , 2001 .
[35] W. S. Hu,et al. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors. , 1996, Blood.
[36] F. Powrie,et al. Regulatory T cells and inflammatory bowel disease. , 1999, Immunology today.
[37] K. Ohta,et al. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. , 1993, Cancer research.
[38] Manish Gala,et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.
[39] R. Moy,et al. Local expression of antiinflammatory cytokines in cancer. , 1993, The Journal of clinical investigation.
[40] T. Tsushima,et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. , 2001, Cancer.
[41] K. Yasumoto,et al. Autologous Tumor‐specific Cytotoxic T Lymphocytes in a Patient with Lung Adenocarcinoma: Implications of the Shared Antigens Expressed in HLA‐A24 Lung Cancer Cells , 1998, Japanese journal of cancer research : Gann.
[42] S. Dubinett,et al. Human Non-Small Cell Lung Cancer Cells Express a Type 2 Cytokine Pattern 1 , 2006 .
[43] M. Washington,et al. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. , 1996, Lung cancer.